# Title
Effects O
of O
St O
John's O
wort O
and O
CYP2C9 B-Gene
genotype O
on O
the O
pharmacokinetics O
and O
pharmacodynamics O
of O
gliclazide. B-Chemical

# Abstract
BACKGROUND O
AND O
PURPOSE: O
Patients B-Species
commonly O
take O
complementary O
medicines O
in O
conjunction O
with O
conventional O
drugs O
without O
clear O
evidence O
of O
safety O
or O
the O
risk O
of O
herb-drug O
interactions. O
The O
aim O
of O
this O
study O
was O
to O
assess O
potential O
pharmacokinetic O
(PK) O
and O
pharmacodynamic O
(PD) O
interactions O
between O
St O
John's O
wort O
and O
gliclazide B-Chemical
in O
healthy O
subjects O
with O
different O
cytochrome B-Gene
P450 I-Gene
2C9 I-Gene
(CYP2C9) B-Gene
genotypes. O
EXPERIMENTAL O
APPROACH: O
A O
crossover O
controlled O
study O
was O
conducted O
in O
21 O
healthy O
subjects. O
Each O
received O
gliclazide B-Chemical
(80 O
mg) O
either O
alone O
or O
during O
15 O
days O
treatment O
with O
St O
John's O
wort. O
The O
area O
under O
the O
plasma O
concentration-time O
curve O
(AUC(0-infinity)), O
apparent O
clearance O
(CL O
F) O
and O
elimination O
half-life O
(t O
1 O
2) O
of O
gliclazide B-Chemical
and O
incremental O
changes O
in O
glucose B-Chemical
and O
insulin B-Gene
AUC(0-4) O
were O
compared. O
CYP2C9*2 O
and O
CYP2C9*3 O
alleles O
were O
identified O
using O
PCR O
followed O
by O
restriction O
enzyme O
digestion O
analysis. O
KEY O
RESULTS: O
St O
John's O
wort O
significantly O
altered O
gliclazide B-Chemical
pharmacokinetics O
in O
all O
except O
for O
four O
healthy O
subjects. O
The O
mean O
ratio O
and O
90% O
confidence O
interval O
(CI) O
of O
gliclazide B-Chemical
AUC(0-infinity) O
and O
CL O
F O
were O
0.67 O
(0.55-0.81) O
and O
1.50 O
(1.24-1.81), O
respectively, O
after O
St O
John's O
wort O
treatment. O
St O
John's O
wort O
decreased O
gliclazide B-Chemical
t O
(1 O
2), O
with O
mean O
ratio O
and O
90% O
CI O
of O
0.85 O
(0.74-0.93). O
There O
were O
no O
significant O
changes O
in O
glucose B-Chemical
or O
insulin B-Gene
AUC(0-4) O
after O
St O
John's O
wort O
treatment O
and O
no O
significant O
differences O
according O
to O
CYP2C9 B-Gene
genotype. O
CONCLUSIONS O
AND O
IMPLICATIONS: O
Treatment O
with O
St O
John's O
wort O
significantly O
increases O
the O
apparent O
clearance O
of O
gliclazide B-Chemical
which O
is O
independent O
of O
CYP2C9 B-Gene
genotype. O
People O
with O
diabetes O
receiving O
this O
combination O
should O
be O
closely O
monitored O
to O
evaluate O
possible O
signs O
of O
reduced O
efficacy. O